You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
榮昌生物(688331.SH):抗體偶聯藥物RC278獲得藥物臨牀試驗申請受理通知書
格隆匯 05-12 15:41

格隆匯5月12日丨榮昌生物(688331.SH)公佈,公司收到國家藥品監督管理局核准簽發的《受理通知書》,新型抗體偶聯(ADC)藥物注射用RC278的臨牀試驗申請獲得受理。RC278 是由榮昌生物自主研發的一款具有 First-in-Class/Best-in-Class潛質的ADC 分子,該分子能特異識別一個新型腫瘤靶點,並具有創新的連接子—毒素系統,在臨牀前研究中展現出廣譜抗腫瘤活性、良好的安全性和藥代動力學特徵,將為晚期實體瘤患者帶來新的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account